Literature DB >> 34053222

Development of an Efficient and Sensitive Chemical Derivatization-Based LC-MS/MS Method for Quantifying Gut Microbiota-Derived Metabolites in Human Plasma and Its Application in Studying Cardiovascular Disease.

Hsin-Yu Liao1,2, Chin-Yi Wang1,2, Ching-Hua Lee1,2, Hsien-Li Kao3, Wei-Kai Wu4, Ching-Hua Kuo1,5,2.   

Abstract

Recently, the gut microbiota has been found to be associated with many diseases, such as inflammatory bowel disease, depression, Parkinson's disease, cancer, metabolic syndrome, and cardiovascular disease (CVD). Among various gut microbiota-derived metabolites (GMs), short-chain fatty acids (SCFAs), bile acids (BAs), and tryptophan (TRP) metabolites are the most frequently discussed metabolites. LC-MS/MS shows advantages in quantifying the levels of metabolites with good sensitivity and selectivity; however, the poor ionization efficiency and polar characteristics of SCFAs make their analysis challenging, especially when analyzing plasma samples with low SCFA concentrations. Moreover, without characteristic fragment ions for unconjugated BAs and different detection ion modes for TRP metabolites and BAs, GM analysis is complex and time-consuming. To overcome these problems, we developed a derivatization method combined with LC-MS/MS to enhance the sensitivity and LC retention of GMs. Through derivatization with 3-nitrophenylhydrazine (3-NPH), 7 SCFAs, 9 bile acids, and 6 tryptophan metabolites can be simultaneously analyzed via separation within 14 min on a reversed-phase C18 column. For accurate quantification, 13C6-3NPH-labeled standards were used as one-to-one internal standards. This derivatization approach was optimized and then validated. We further applied this method to investigate the targeted GM profile in patients with CVD. The results showed a significant reduction in plasma butyrate levels in CVD patients compared with healthy controls, suggesting its potentially protective role in CVD. In summary, this work provides a sensitive and effective LC-MS/MS method for simultaneously quantifying gut microbiota-related metabolites in human plasma, which could benefit various future gut microbiota-related studies.

Entities:  

Keywords:  LC−MS; SCFAs; bile acids; cardiovascular disease; derivatization; gut metabolites

Year:  2021        PMID: 34053222     DOI: 10.1021/acs.jproteome.1c00147

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  3 in total

1.  Development and Validation of a LC-MS/MS Technique for the Analysis of Short Chain Fatty Acids in Tissues and Biological Fluids without Derivatisation Using Isotope Labelled Internal Standards.

Authors:  Shikha Saha; Priscilla Day-Walsh; Emad Shehata; Paul Anthony Kroon
Journal:  Molecules       Date:  2021-10-26       Impact factor: 4.411

2.  Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.

Authors:  Szu-Ju Chen; Chieh-Chang Chen; Hsin-Yu Liao; Ya-Ting Lin; Yu-Wei Wu; Jyh-Ming Liou; Ming-Shiang Wu; Ching-Hua Kuo; Chin-Hsien Lin
Journal:  Neurology       Date:  2022-01-07       Impact factor: 11.800

Review 3.  Short-Chain Carbon Sources: Exploiting Pleiotropic Effects for Heart Failure Therapy.

Authors:  Azariyas A Challa; E Douglas Lewandowski
Journal:  JACC Basic Transl Sci       Date:  2022-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.